CALUSTERONE

US Previously Marketed

First approved in 1973

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H32O2
Molecular Weight	316.4776
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O)[C@H]13

InChI

InChIKey=IVFYLRMMHVYGJH-PVPPCFLZSA-N

InChI=1S/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H32O2
Molecular Weight	316.4776
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/calusterone | http://www.hmdb.ca/metabolites/HMDB0004627

CALUSTERONE is a 17-alkylated androgenic steroid. It may alter the metabolism of estradiol and reduce estrogen production. As an androgen, CALUSTERONE was used as a therapeutic agent in postmenopausal women with metastatic breast cancer.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast Cancer 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/190574	Primary		Withdrawn	Methosarb Approved Use Unknown

T_1/2

Value	Dose	Co-administered	Analyte	Population
24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/161435/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		CALUSTERONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5457511	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/5457511	Other AEs: Acne... Other AEs: Acne (severe, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/5457511
200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/141327	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/141327	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (25%) Vomiting (25%) Fluid retention (25%) SGOT increased (25%) Sources: https://pubmed.ncbi.nlm.nih.gov/141327

AEs

AE	Significance	Dose	Population
Acne	severe, 1 patient	300 mg 1 times / day multiple, oral Studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/5457511	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/5457511
Fluid retention	25% Disc. AE	200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/141327	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/141327
Nausea	25% Disc. AE	200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/141327	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/141327
SGOT increased	25% Disc. AE	200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/141327	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/141327
Vomiting	25% Disc. AE	200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/141327	unhealthy Health Status: unhealthy Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/141327

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L1EU7
AHH Chemical co.,ltd	MT-41423	http://www.ahhchemical.com/product/MT-41423.html
Alfa Chemistry	ACM17021260	https://www.alfa-chemistry.com/4-androsten-7-17-dimethyl-17-ol-3-one-cas-17021-26-0-item-26736.htm
Chemieliva Pharmaceutical Co., Ltd	PBCM1211696
Compound Cloud	28204
NCI Plated 2007	66233
NCI Plated 2007	88536
NovoSeek	28204
Smolecule	S522531	http://www.smolecule.com/products/s522531
Tetrahedron	TS76858
THE BioTek	bt-262562	https://www.thebiotek.com/product/inhibitors/bt-262562
ZINC	ZINC000004215173	http://zinc15.docking.org/substances/ZINC000004215173

PubMed

Title	Date	PubMed
MR appearance of intra-abdominal metastatic melanoma.	1992	1501542
Calusterone therapy for advanced breast cancer.	1977-05-01	141327
Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer.	1973	4583006

Patents

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:20:46 GMT 2025` Edited by `admin` on `Mon Mar 31 18:20:46 GMT 2025`
Record UNII	0678G6Q58A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHOSARB

Preferred Name

English

CALUSTERONE

Official Name

English

ANDROST-4-EN-3-ONE, 17-HYDROXY-7,17-DIMETHYL-, (7.BETA.,17.BETA.)-

Common Name

English

U-22550

Code

English

calusterone [INN]

Common Name

English

CALUSTERONE [MI]

Common Name

English

7.BETA.,17.ALPHA.-DIMETHYLTESTOSTERONE

Common Name

English

Calusterone [WHO-DD]

Common Name

English

NSC-88536

Code

English

17?-Hydroxy-7?,17-dimethylandrost-4-en-3-one

Systematic Name

English

7.BETA.,17.ALPHA.-DIMETHYL-17.BETA.-HYDROXYANDROST-4-EN-3-ONE

Systematic Name

English

CALUSTERONE [HSDB]

Common Name

English

U-22,550

Code

English

DIMETHYLTESTOSTERONE

Common Name

English

CALUSTERONE [MART.]

Common Name

English

CALUSTERONE [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C243